Article

Mutation-independent cystic fibrosis treatment by opening calcium-activated chloride channel with a novel GPR39 agonist, DS-1039

2023-06-15

Abstract excerpt

<title>Abstract</title> <p>Cystic fibrosis (CF) is a life-limiting genetic disease characterized by decreased chloride and water secretion and caused by loss-of-function mutations in CF transmembrane conductance regulator (CFTR), an epithelial chloride channel. Here, we report DS-1039, an orally active GPR39 agonist, as a novel pharmacological agent to rescue CFTR dysfunction by activating calcium-activated chlor...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 072b7787-e3d7-5a85-913a-9e1194c6a95b
DOI: 10.21203/rs.3.rs-2932546/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Mutation-independent cystic fibrosis treatment by opening calcium-activated chloride channel with a novel GPR39 agonist, DS-1039DOI 10.21203/rs.3.rs-2932546/v1Read

Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.Semantic proximity Read

Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence.Semantic proximity Read

Drug repurposing for Cystic Fibrosis: identification of drugs that induce CFTR-independent fluid secretion in nasal organoidsSemantic proximity Read

Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis.Semantic proximity Read

Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251).Semantic proximity Read

The G551D CFTR chloride channel spurs the development of personalized medicine.Semantic proximity Read

Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation.Semantic proximity Read

Theratyping of the Rare CFTR Genotype A559T in Rectal Organoids and Nasal Cells Reveals a Relevant Response to Elexacaftor (VX-445) and Tezacaftor (VX-661) Combination.Semantic proximity Read

Systemic bis-phosphinic acid derivative restores chloride transport in Cystic Fibrosis mice.Semantic proximity Read

In Silico Evaluation of Lumacaftor for Cystic FibrosisSemantic proximity Read

Peptide CIGB-552 has a synergistic effect on CFTR-F508del combined with Elexacaftor/Tezacaftor/IvacaftorSemantic proximity Read

Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist.Semantic proximity Read